A Positive Antibody at a Routine Visit: A Comprehensive Plan and Coding for Newly Found Chronic Hepatitis C in a 58-Year-Old Man, From Confirmation to a Cure in Primary Care
[Student Name]
University of Phoenix
NRP/555: Adult and Geriatric Management I
Week 8 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper. Coding details should be checked against current code sets.
Mr. S., a 58-year-old warehouse manager, had a routine visit last month and agreed to hepatitis C screening. His hepatitis C antibody was positive. He is surprised; he recalls injecting drugs twice in his twenties and received a blood transfusion after a car accident in 1988. He has no symptoms, drinks two beers on weekends and takes lisinopril for hypertension. This paper presents the comprehensive plan and coding.
Why He Was Screened
Federal preventive guidance now calls for a hepatitis C test in every adult between 18 and 79 (U.S. Preventive Services Task Force et al., 2020). The CDC recommends screening all adults at least once, and all pregnant people during each pregnancy, except in settings with very low prevalence (Schillie et al., 2020). Universal screening finds people like Mr. S. who would not have been tested based on risk questions alone, since many do not recall or disclose past exposures.
Confirming Active Infection
A positive antibody means exposure at some point but not necessarily current infection, since about a quarter of people clear the virus. The CDC recommends that a positive antibody be followed by a nucleic acid test for hepatitis C RNA (Schillie et al., 2020). Mr. S.'s viral load is 1.8 million IU/mL, confirming chronic infection.
Pretreatment Assessment
The AASLD-IDSA guidance's simplified pathway for treatment-naive adults without cirrhosis requires a limited pretreatment evaluation: assessment for cirrhosis using a noninvasive score such as FIB-4, a complete blood count, liver function tests, estimated kidney function, hepatitis B surface antigen, HIV testing, a pregnancy test when relevant and a medication review for drug interactions (Ghany et al., 2020). Mr. S.'s FIB-4 score is 1.1, which makes advanced fibrosis unlikely. His platelets, albumin and bilirubin are normal; alanine aminotransferase is 78 U/L. Hepatitis B surface antigen and HIV are negative. His hepatitis B core antibody is positive, indicating past infection, which matters because hepatitis B can reactivate during hepatitis C treatment.
A single positive screen became a curable diagnosis in the same clinic that ordered the test.
Treatment Choice
The simplified pathway recommends either glecaprevir-pibrentasvir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks for treatment-naive adults without cirrhosis, regardless of genotype (Ghany et al., 2020). Both achieve cure rates above 95%. I choose sofosbuvir-velpatasvir, one tablet daily for 12 weeks, because his insurance's preferred product list includes it and because he prefers once-daily dosing with one tablet. I check for interactions: lisinopril is compatible; he should avoid acid-reducing medicines, which reduce velpatasvir absorption, or take them only as directed.
Hepatitis B Precaution
Because his core antibody is positive with a negative surface antigen, the guidance advises monitoring liver tests during and after treatment for possible hepatitis B reactivation, which is rare in this situation. I will check liver tests at the end of treatment and if he develops symptoms.
Monitoring and Cure
Under the simplified pathway, routine laboratory monitoring during treatment is not required for most patients, but adherence support is important. Cure, or sustained virologic response, is confirmed by an undetectable viral load 12 weeks after completing treatment (Ghany et al., 2020).
Prevention and Counseling
I counsel Mr. S. to limit alcohol while his liver heals, to avoid sharing razors or toothbrushes and that the risk of sexual transmission in a monogamous relationship is low. His wife is offered screening. I recommend hepatitis A vaccination, since he lacks immunity, and discuss hepatitis B vaccination; with a positive core antibody, he does not need it. Cure does not protect against reinfection.
Why Primary Care
For years, hepatitis C treatment required specialist care because of complex regimens, injections and serious side effects. Current pangenotypic direct-acting antivirals are taken by mouth, are well tolerated and cure most patients, which is why the guidance describes a simplified pathway suitable for primary care (Ghany et al., 2020). Treating in primary care reduces the number of steps between diagnosis and cure, a point where many patients were lost when referral was required.
When to Refer
The simplified pathway does not apply to everyone. Patients with cirrhosis, prior treatment failure, hepatitis B surface antigen positivity, HIV, pregnancy, kidney failure or a liver transplant need a specialist or a modified approach (Ghany et al., 2020). If Mr. S.'s FIB-4 had been high, I would have obtained elastography before deciding.
Adherence Support
Missing doses lowers cure rates. I set up pharmacy delivery with refill reminders, ask Mr. S. to link the pill to his morning coffee and ask the clinic nurse to call at two and six weeks. He is motivated and has stable housing, which predicts good adherence.
Insurance Approval
Some insurers require prior authorization. The clinic's medication assistance coordinator will submit the request with the viral load and FIB-4 score, and I will start treatment as soon as it is approved.
Coding
Diagnosis codes: chronic viral hepatitis C, B18.2; essential hypertension, I10. The positive hepatitis B core antibody may be documented as a finding. The visit addressed a new chronic illness requiring workup and a new prescription drug, and reviewed multiple test results: problems moderate, data moderate and risk moderate, supporting a moderate-complexity established patient visit, 99214, by medical decision making. Documentation includes the laboratory results reviewed, the FIB-4 calculation, the treatment decision and the counseling.
Side Effects to Expect
Sofosbuvir-velpatasvir is generally well tolerated; headache and fatigue are the most common side effects and are usually mild. I ask Mr. S. to call if he develops yellowing of the eyes, dark urine or severe abdominal pain, which would be unusual but could signal liver injury or hepatitis B reactivation.
Reducing Stigma
Mr. S. was embarrassed about his past drug use. I reassured him that many people with hepatitis C were infected decades ago, that the infection says nothing about who he is now and that curing it protects his health and his family.
Reporting
Hepatitis C is a reportable condition, and the laboratory result will be reported to the state health department as required, which supports public health surveillance and does not affect his care.
Follow-Up
Phone check at two weeks for side effects and adherence; visit at the end of treatment; viral load 12 weeks after treatment to confirm cure. Because his FIB-4 is low, he will not need ongoing liver cancer surveillance after cure, although persistently raised liver enzymes after cure would prompt evaluation.
Conclusion
Universal screening found Mr. S.'s chronic hepatitis C, and a viral load confirmed active infection. A simplified pretreatment evaluation showed no cirrhosis and a past hepatitis B infection that calls for monitoring. A 12-week course of sofosbuvir-velpatasvir under the AASLD-IDSA simplified pathway, with vaccination, counseling and a post-treatment viral load to confirm cure, allows primary care to take him from a positive screen to a cure, with coding that reflects the complexity of the work.
References
Ghany, M. G., Morgan, T. R., & AASLD-IDSA Hepatitis C Guidance Panel. (2020). Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology, 71(2), 686-721. https://doi.org/10.1002/hep.31060
Schillie, S., Wester, C., Osborne, M., Wesolowski, L., & Ryerson, A. B. (2020). CDC recommendations for hepatitis C screening among adults: United States, 2020. MMWR Recommendations and Reports, 69(2), 1-17. https://doi.org/10.15585/mmwr.rr6902a1
U.S. Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Donahue, K., Doubeni, C. A., Epling, J. W., Jr., Kubik, M., Ogedegbe, G., Pbert, L., Silverstein, M., Simon, M. A., Tseng, C.-W., & Wong, J. B. (2020). Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA, 323(10), 970-975. https://doi.org/10.1001/jama.2020.1123
How this NRP 555 Week 8 example is structured
The NRP/555 Week 8 work usually closes with a comprehensive adult case, coding and a full management plan. This paper integrates screening recommendations, confirmation, staging, treatment selection, documentation for coding and follow-up for a condition that primary care can now cure. Students search this week as NRP 555 Week 8, NRP555 Wk 8 or NRP/555 Wk 8; all three are the same assignment.
NRP/555 Week 8 questions, answered
What does NRP/555 Week 8 usually ask for?
Many sections close with a comprehensive adult or older adult case requiring a full management plan, often with ICD-10 coding and evaluation and management level.
Who should be screened for hepatitis C?
The USPSTF recommends screening all adults aged 18 to 79, and the CDC recommends screening all adults at least once and pregnant people during each pregnancy.
Can hepatitis C be treated in primary care?
Yes. The AASLD-IDSA guidance describes a simplified approach for treatment-naive adults without cirrhosis, using 8 or 12 weeks of pangenotypic direct-acting antivirals with minimal monitoring.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.